UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000012200 |
|---|---|
| Receipt number | R000014218 |
| Scientific Title | Effect of diease-modifying and biological drugs on intestinal immunity in patients with rheumatoid arthritis. |
| Date of disclosure of the study information | 2013/11/01 |
| Last modified on | 2019/11/07 10:17:52 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effect of diease-modifying and biological drugs on intestinal immunity in patients with rheumatoid arthritis.
Acronym
Anti-rheumatic drugs, biologicals and intestinal immunity.
Scientific Title
Effect of diease-modifying and biological drugs on intestinal immunity in patients with rheumatoid arthritis.
Scientific Title:Acronym
Anti-rheumatic drugs, biologicals and intestinal immunity.
Region
| Japan |
Condition
Condition
Rheumatoid arthritis
Classification by specialty
| Clinical immunology | Orthopedics |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to revieal the effects of DMARDs and biological drugs on intestinal immunity of pateients with RA for further improving therapeutic strategies.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase IV
Assessment
Primary outcomes
a) Therapeutic effects of DMARDs and biologicals will be evaluated by EULAR and ACR criteria.
b) Antibody response to E. coli and LPS
will be assayed to determine intestinal immune function of individual pateints, whereas serum LPS levels will be determined to measure intestinal barrier function. In addition, serum TNF, IL-6 and anti-CCP antibody levels will be
assayed to study the potential linkage between intestinal immune function and inflamation.
c) Effect of RMARDs and biologicals on intestinal immune function will be evaluated in individual patients for a 6-month period as well as for their their therapeutic effect.
Key secondary outcomes
This study will provide basic data to study a new concept that lowered immune function may be the fundamental common disorder in autoimmune diseases.
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Three groups of RA patients of each consisting of 20 and more persons will be studied for at least 6 months. A group ofhealthy persons will be addopted as a control.
1) Untreated RA patients, before and after treatment with DMARDs.
2) RA patients during treatment with DMARs.
3) DMARDs resistant RA patient, before and after treatement with biologicals.
4) Normal adults
Key exclusion criteria
RA patients having complication other than rheumatoid arthritis
Target sample size
80
Research contact person
Name of lead principal investigator
| 1st name | Kou |
| Middle name | |
| Last name | Katayama |
Organization
Katayama Orthopedic Rheumatology Clinic
Division name
Department of orthopedic surgery
Zip code
078-8243
Address
Toyooka 13-4-5-17 Asahikawa Hokkaido Japan
TEL
0166-39-1155
kou@kata-rheum.or.jp
Public contact
Name of contact person
| 1st name | Kou |
| Middle name | |
| Last name | Katayama |
Organization
Katayama Orthopedic Rheumatology Clinic
Division name
Department of orthopedic surgery
Zip code
078-8243
Address
Toyooka 13-4-5-17 Asahikawa Hokkaido Japan
TEL
0166-39-1155
Homepage URL
http://www.kata-rheum.or.jp/dr_info.html
kou@kata-rheum.or.jp
Sponsor or person
Institute
Katayama Orthopadic Rheumatology Clinic
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Chondrex Inc.
Asama-chemical Co. Ltd.
Seien Drugs Compounding Co. Ltd
Name of secondary funder(s)
None
IRB Contact (For public release)
Organization
Asahikawa Medical University Research Ethics Committee
Address
1-1-1 Higashi 2 jou midorigaoka Asahikawa Japan
Tel
0166-68-2187
sho-kenkyu@jimu asahikawa-med.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
片山整形外科リウマチ科クリニック（北海道）、Katayama Orthopadic Rheumatology Clinic (Hokkaido)
コンドレックスインク（レッドモンド,WA,USA), Chondrex Inc (Redmond, WA,USA)
アサマ化成株式会社（東京都）、Asama-chemical Co.Ltd (Tokyo)
株式会社深井薬局（北海道）、Seien Drugs Compounding (Hokkaido)
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 11 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Patients of Rheumatoid arthritis(RA),
dividing into two pathogenisis of rapid rediographic progression(RRP) and non-RRP,
were assyed for their IgA and IgG antibody activity to E coli-LPS, Gingivalis LPS and St. pyogenes PG-PS and compared with those of normal person. No significant differenses was obserbed between RA and normal. Correlation between RA disease markers,RF, ESR, CRP and also DAS28-ESR to an anti IgA/IgG ratio of Pg-LPS correlated in RRP. In contrast,the ratio to E. coli-LPS and also PG-PS correlated with the disease markers in non-RRP. Results shwed that multiple embironmental pathogen, which overwhelm the host antibody defense function, cotribute independently or concomitantly to evoking disease markers and aggravationg disease activity, and affect disease outcomes.
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2013 | Year | 10 | Month | 31 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 11 | Month | 01 | Day |
Last follow-up date
| 2017 | Year | 05 | Month | 09 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
| 2017 | Year | 12 | Month | 31 | Day |
Other
Other related information
The present study is designed on the hypothesis that increased mucosal permeability associated with low immune function at gut lymphoid tissue may be the fundamental, common disorder in autoimmune diseases. In parallel with the treatment of rheumatoid arthritis, a search is performed with a focus on gastrointestinal immune function and gut permeability and to test the hypothesis.
Management information
Registered date
| 2013 | Year | 11 | Month | 01 | Day |
Last modified on
| 2019 | Year | 11 | Month | 07 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014218
